Enrichment of Sialylated IgG by Lectin Fractionation Does Not Enhance the Efficacy of Immunoglobulin G in a Murine Model of Immune Thrombocytopenia
Open Access
- 23 June 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6), e21246
- https://doi.org/10.1371/journal.pone.0021246
Abstract
Intravenous immunoglobulin G (IVIg) is widely used against a range of clinical symptoms. For its use in immune modulating therapies such as treatment of immune thrombocytopenic purpura high doses of IVIg are required. It has been suggested that only a fraction of IVIg causes this anti immune modulating effect. Recent studies indicated that this fraction is the Fc-sialylated IgG fraction. The aim of our study was to determine the efficacy of IVIg enriched for sialylated IgG (IVIg-SA (+)) in a murine model of passive immune thrombocytopenia (PIT). We enriched IVIg for sialylated IgG by Sambucus nigra agglutinin (SNA) lectin fractionation and determined the degree of sialylation. Analysis of IVIg-SA (+) using a lectin-based ELISA revealed that we enriched predominantly for Fab-sialylated IgG, whereas we did not find an increase in Fc-sialylated IgG. Mass spectrometric analysis confirmed that Fc sialylation did not change after SNA lectin fractionation. The efficacy of sialylated IgG was measured by administering IVIg or IVIg-SA (+) 24 hours prior to an injection of a rat anti-mouse platelet mAb. We found an 85% decrease in platelet count after injection of an anti-platelet mAb, which was reduced to a 70% decrease by injecting IVIg (p<0.01). In contrast, IVIg-SA (+) had no effect on the platelet count. Serum levels of IVIg and IVIg-SA (+) were similar, ruling out enhanced IgG clearance as a possible explanation. Our results indicate that SNA lectin fractionation is not a suitable method to enrich IVIg for Fc-sialylated IgG. The use of IVIg enriched for Fab-sialylated IgG abolishes the efficacy of IVIg in the murine PIT model.Keywords
This publication has 32 references indexed in Scilit:
- Analytical and Functional Aspects of Antibody SialylationJournal of Clinical Immunology, 2010
- Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disordersVox Sanguinis, 2010
- 6th International Immunoglobulin Symposium: Poster presentationsClinical and Experimental Immunology, 2009
- A close look at human IgG sialylation and subclass distribution after lectin fractionationProteomics, 2009
- Identification of a receptor required for the anti-inflammatory activity of IVIGProceedings of the National Academy of Sciences, 2008
- Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG FcScience, 2008
- Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serumProteomics, 2007
- Mechanisms of Intravenous Immunoglobulin Action in Immune Thrombocytopenic PurpuraHuman Immunology, 2005
- Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseasesClinical and Experimental Immunology, 1991
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOODThe Lancet, 1981